JON ERIC SPRAGUE
ADDRESS:
Office: 29 College Park Home: 64 Anna Circle
Bowling Green State University Bluffton, OH 45817
Bowling Green, OH 43403
Phone: 419-372-0224
e-mail:
EDUCATION:
1991-'94 Ph.D. in Pharmacology and Toxicology
Department of Pharmacology and Toxicology
School of Pharmacy and Pharmacal Sciences
Purdue University
1984-'89 B.S. in Pharmacy (Distinction)
Ferris State University
PROFESSIONAL EXPERIENCE:
2014-present Director of the Ohio Attorney General’s Center for the Future of the Forensic Sciences
Bowling Green State University
2013-2014 Director of Academic Research (University)
Ferrris State University
2013-2014 Director of Research & Discovery (College)
Head of Pharmaceutical Sciences
Professor of Pharmacology
College of Pharmacy
Ferris State University
Big Rapids, MI 49307
2006-2013 Dean and Professor of Pharmacology
The Raabe College of Pharmacy
Ohio Northern University
Ada, Ohio 45810
2011 Aileron (consultant)
Dayton, OH
2004-2006 Chairman and Professor of Pharmacology
Virginia College of Osteopathic Medicine &
Department of Biomedical Sciences and Pathobiology
Virginia Polytechnic Institute and State University
Blacksburg, VA 24060
1998-2004 Associate Professor of Pharmacology
Department of Pharmaceutical & Biomedical Sciences
School of Pharmacy
Ohio Northern University
Ada, Ohio
PROFESSIONAL EXPERIENCE CONTINUED:
1995-‘98 Assistant Professor of Pharmacology
Department of Pharmaceutical & Biomedical Sciences
School of Pharmacy
Ohio Northern University
Ada, Ohio
1997-2000 Visiting Scientist
Parke Davis
Neurological and Neurodegenerative Diseases
Ann Arbor, MI
1997 Interim Director
Drug Information Center
Ohio Northern University
Ada, Ohio
1995 Consultant
United States Department of Transportation
1994-'95 Visiting Assistant Professor of Pharmacology
Department of Pharmacology and Toxicology
School of Pharmacy and Pharmacal Sciences
Purdue University
West Lafayette, Indiana
1992-'93 Pharmacology and Toxicology Tutor
School of Pharmacy and Pharmacal Science
Purdue University
West Lafayette, Indiana
1991-'95 Staff Pharmacist
Wells Yeager Best Pharmacy
Lafayette, Indiana
1991-'94 Graduate Teaching Assistant
Department of Pharmacology and Toxicology
School of Pharmacy and Pharmacal Sciences
Purdue University
West Lafayette, Indiana
1989-'91 Staff Pharmacist/Assistant Manager
Hooks Drugs
Columbia City, Indiana
1985-'89 Pharmacy Intern
Hooks Drugs
Angola, Indiana
HONORS AND AWARDS:
2014 Ferris State University P1 Outstanding Professor Award
2014 Ferris State University Phi Lambda Sigma Leadership Award
2012-2013 Ohio Northern Mortor Board “Favorite” Professor Award
2012 Omicron Delta Kappa Leadership
2012 Kudos for Klondike Award
2012 Ohio Northern Mortor Board “Favorite” Professor Award
2006-2007 ONU Campus Outstanding Faculty Member
2006 WVU Bergy Lecturer Recognition Award
2006 VCOM Student Professor Recognition Award
2004 ONU Outstanding Professor Award, Ohio Northern University
2002 Pharmacy Alumni Chair Award, Ohio Northern University
2002 Outstanding Overall Professor, Ohio Northern University
2002 P-4 Outstanding Professor Award, Ohio Northern University
2002 Student-Athlete Advisor Committee Distinguished Professor
2001 Alpha Xi Delta Professor of the Month
1995-2000 AACP Teacher of the Year Recognition
2000 P-4 & P-5 Outstanding Professor Award, Ohio Northern University
1995-2003 Ohio Northern Mortor Board “Favorite” Professor Award
1999 Excellence in Teaching Award (ONU highest teaching award)
1998 P-5 Outstanding Professor Award
1997 P-5 Outstanding Professor Award
1997 Panhellenic Council Teachers Recognition
1996 Outstanding Professor Award, Ohio Northern University
1996 AACP Innovative Teaching Award
1993-95 Kienly Teaching Award, Purdue University
1994 Purdue University Neuroscience Research Award
1993 ASPET Research Travel Award
1992-'94 David Ross Fellowship Recipient
ENTREPRENEURIAL EXPERIENCE AND PATENTS:
2008-present Co-Founder and Director of Technology, Genomic Guidance, LLC. Ada, Ohio.
Patent: Sprague JE, Kane MD, Springer JA, and Iannotti NV. Method for Utilizing Patient Genotyping for Drug Safety. 61/031,527. 2008.
PROFESSIONAL MEMBERSHIPS:
2006-present American Pharmacists Association
2006-present American Society of Health-Systems Pharmacists
2006-present Ohio Pharmacist Association
2001-present American Society for Pharmacology & Experimental Therapeutics
2001-2010 Council for Undergraduate Research
1999-present Mortor Board
1998-present Phi Kappa Phi
1995-98 New York Academy of Sciences
1995 Honorary Membership to Phi Delta Chi
1994-present Society of Neuroscience
1994-97 Sigma XI
1993-present American Association of Colleges of Pharmacy
1991-1995 Purdue University Neuroscience
1989-present Licensed Pharmacist: State of Indiana; State of Ohio
PEER REVIEWED PUBLICATIONS:
Worst TJ, Sprague JE. The “pharmacophore rule” and the spices. Forensic Toxicol. On line pub. September 2014.
Banks ML, Worst TJ, Rusyniak DE, Sprague JE. The synthetic cathinones (the “bath salts”). J Em Med. 46(5):632-642; 2014.
Tuteja S, Haynes K, Sprague JE, Bernhardt B, Pyeritz R. Community pharmacists’ attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Personalized Med 10(8):793-800; 2013.
Kisor DF, Sprague JE. The application of drug-dosing guidelines based on preemptive genetic testing. Speciality Pharmacy Times. May/June 2013.
Kisor DF, Kane MD, Talbot JT, Sprague JE. Pharmacogenetics, Kinetics and Dynamics for
Personalized Medicine. 1st Ed. Jones and Bartlett Learning. Burlington, MA. 2013 (Textbook).
Springer JA, Iannotti NV, Sprague JE, Kane MD. Construction of a drug safety assurance information system based on clinical genotyping. ISRN Bioinformatics. Article ID 982737; 2012.
Hrometz SL, Thatcher KE, Ebert JA, Mills EM, Sprague JE. Identification of a possible role for atrial natriuretic peptide in MDMA-induced hyperthermia. Toxicol. Lett. 206(2): 234-237; 2011.
Springer JA, Iannotti NV, Kane MD, Haynes K, Sprague JE. Teaching Drug Safety and Pharmacogenomics: A Practicum Learning Environment Enabled by a Dedicated Pharmacogenomics Instructional Software System. Amer. J. Pharm. Edu. 75(2):32; 2011.
Banks ML, Sprague JE. From bench to bedside: understanding the science behind the pharmacologic management of the sympathomimetic MDMA-mediated hyperthermia. J. Pharmacy Tech. 27:123-131; 2011.
Zorek JA, Sprague JE, Popovich NG. Bulimic Learning. Amer. J. Pharm. Edu. 74(8): 157; 2010.
Likovich M, Derr A, Kane MD, Kisor DF, Sprague JE. Personalized medicine and the future of pharmacy practice. Pharmacy Times. 410: 106-115; 2010.
Sprague JE. The fifteen year thank you. Amer. J. Pharm. Edu. 74(2):32-33; 2010.
Banks ML, Haynes K, Sprague JE. A model for motivating PharmD students to pursue a PhD degree. Currents Pharm Teaching Learning. 1:93-97; 2009.
Springer JA, Beever J, Morar N, Sprague JE, Kane MD. “Ethics, Privacy, and the Future of Genetic Information in Healthcare Information Assurance and Security” in Information Assurance and Security Ethics in Complex Systems: Interdisciplinary Perspectives, editor Melissa Dark. IGI Global, Hershey, PA. 2010, 186-205.
Banks ML, Buzard SK, Gehret CM, Monroy AN, Kenaston MA, Mills EM, Sprague JE. Pharmacodynamic characterization of insulin in MDMA-induced thermogenesis. Eur. J. Pharmacol. 615(1-3):257-61, 2009.
Wyeth RP, Mills EM, Ullman A, Kenaston MA, Burwell J, Sprague JE. The hyperthermia mediated by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) is sensitive to sex differences. Toxicol. Appl. Pharmacol. 235(1):33-8, 2009.
Sprague JE, Sullivan DL, Kane MD. Personalized Medicine: Pharmacogenetics as a method for improving patient outcomes. Ohio Pharmacists. 57(11):13-19, 2008.
PEER REVIEWED PUBLICATIONS CONTINUED:
Kane MD, Springer JA, Sprague JE. Drug safety assurance through clinical genotyping: near-term
Considerations for a system-wide implementation of personalized medicine. Personalized Med. 5(4): 1-11, 2008.
Banks ML, Czoty PW, Sprague JE, Nader MA. Influence of thyroid hormones on 3,4-methylenedioxymethamphetamine-induced thermogenesis and reinforcing strength in monkeys. Behavioural Pharmacol. 19(2):167-70, 2008.
Banks ML, Sprague JE, Czoty PW, Nader MA. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacol (Berl). 196(1): 63-70, 2008.
Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, Nader MA. Ambient temperature effects on 3,4-methylenedioxymethamphetamine (MDMA)-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos. 35(10): 1840-1845, 2008.
Mills EM, Weaver KL, Abramson E, Pfeiffer M, Sprague JE. Influences of dietary fats on ecstasy-induced hyperthermia. Br. J. Pharmacol. 151(7):1103-1108, 2007.
Sprague JE, Yang X, Sommers J, Gilman TL, Mills EM. Roles of norepinephrine, free Fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis. J Pharmacol Exp Ther. 320(1):274-280; 2007.
Banks ML, Czoty PW, Sprague JE, Nader MA. Influence of ambient temperature on a primate model of MDMA (Ecstasy) abuse. In: Di Chiara G, Carbon E, Valentini V, Aquas E, Bassareo V, Cadoni C, eds, “Monitoring Molecules in Neuroscience: Proceeding of the 11th International Conference on In Vivo Methods”. University of Cagliari, Cagliari, Italy, 2006, pp. 398-400.
Peterson AL, Gilman TL, Banks ML, Sprague JE. Hypothyroidism alters striatal dopamine release mediated by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). Synapse. 59(5):317-319; 2006.
Rusyniak DE, and Sprague JE. Toxin-induced hyperthermic syndromes. Med. Clin. N. Am. 89(6):1277-1296, 2005. (invited review).
Sprague JE, Moze P, Caden D, Rusyniak DE, Holmes C, Goldstein DS, Mills EM. Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model. Crit Care Med. Jun;33(6):1311-6, 2005.
Sprague JE, Nichols DE. Neurotoxicity of MDMA (ecstasy): beyond metabolism. Trends Pharmacol Sci 26(2):59-60, 2005.
Rusyniak DE, Tandy SL, Hekmatyar SN, Mills E, Smith DJ, Bansal N, Maclellan D, Harper ME, Sprague JE. The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine mediated skeletal muscle hyperthermia and rhabdomyolysis. J Pharmacol Exp Ther. 313(2):629-39; 2005.
Mills, E. Rusyniak, D.E. and Sprague, J.E. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med. 82(12):787-99, 2004 (invited review).
Sprague, J.E., Mallet, N.M., Rusyniak, D.E., and Mills, E. UCP3 and thyroid hormone involvement in methamphetamine-induced hyperthermia. Biochem. Pharmacol. 68(7):1339-1343, 2004.
PEER REVIEWED PUBLICATIONS CONTINUED:
Hrometz, S.L., Brown, A.W., Nichols, D.E., and Sprague, J.E. 3,4-methylenedioxymethamphetamine (MDMA,ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci Lett. 367(1):56-59, 2004
Sprague, J.E., Brutcher, R.E., Mills, E. M., Caden, D., and Rusyniak, D.E. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) induced rhabdomyolysis with α1- plus β3-adrenoreceptor antagonists. Br. J. Pharmacol. 142(4):667-670, 2004.
Rusyniak, D.E., Banks, M.L., Mills, E. M., and Sprague, J.E. Dantrolene use in MDMA (Ecstasy) mediated hyperthermia. Anesthesiology. 101(1):263-264, 2004.
Rusyniak, D.E., Scruggs, S.L., Kamendulis, L.M., Sprague, J.E., and Klaunig, J.E. The effects of ecstasy (MDMA) on rat liver bioenergetics. Acad. Emer. Med. 11(7):723-729, 2004.
Mills, E.M., Banks, M.L., Sprague, J.E., and Finkel, T. Uncoupling the agony from
ecstasy. Nature. 426:403-404, 2003.
Sprague, J.E., Banks, M.L., Cook, V.J., and Mills, E. Hypothalamic-Pituitary-Thyroid axis and sympathetic nervous system involvement in the hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). J. Pharmacol. Exp. Ther. 305(1):159-166, 2003.
Sprague, J.E., Preston, A.S., Leifheit, M., and Woodside, B. Hippocampal Serotonergic Damage induced by MDMA (Ecstasy): Effects on Spatial Learning. Physiol. Behav. 79:281-287, 2003.
Kane, M.D., Lin, H-S, Dombkowski, A.A., Diakiw, A., Nagel, A.C., Flexon, A., Leifheit, M., Sprague, J.E. and Hollenberg, P.F. Accelerating Preclinical Drug Development Using A Microarray-Based Method for Detecting Oxidative Enzyme (P450) mRNA Induction and Other Metabolic Genes in the Rat. In: Hardiman, G., editor. Microarray Methods and Applications: Nuts & Bolts. DNA Press, 2003; pp. 231-248.
Kanthasamy, A., Sprague, J.E., Shotwell, J.R., and Nichols, D.E. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience. 114(4):917-924; 2002.
Waites, N.S., and Sprague, J.E. Pharmacology and Toxicology of Ecstasy. U.S. Pharmacist. June 2002.
Falk, E.M., Cook, V., Nichols, D.E and Sprague, J.E. Antisense targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol. Biochem. Behav. 72:617-622; 2002.
Sprague, J.E., Leifheit, M., Selken, J., Milks, M.M., Kinder, D.H., and Nichols, D.E. In vivo Microdialysis and Conditioned Place Preference Studies in Rats are Consistent with Abuse Potential of Tramadol. Synapse. 43:118-121, 2002.
Elick, K., and Sprague, J.E. Renal and muscle damage induced by the statins. Pharmacy Times. 67(9):22-25, 2001.
Sprague, J.E. Teaching Cardiac Arrhythmias: A focus on pathophysiology and pharmacology. Amer. J. Pharm. Educ. 65:169-177, 2001.
Sprague, J.E.; Worst, T.J.; Haynes, K.; Mosler, C.R.; Nichols, D.E.; Kane, M.D. The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue. Cellular Molecular Neuro Bio. 21(1):53-64, 2001.
PEER REVIEWED PUBLICATIONS CONTINUED:
Jutte, S.B. and Sprague, J.E. An overview of the physiological and pathological roles of the renin-angiotensin system: a focus on the pharmacological regulation. J. Pharmacy Tech. 16:138-146, 2000.
Sprague, J.E.; Christoff, J.; Allison, J.; Kisor, D.; Sullivan, D. Development and Implementation of
an Integrated Cardiovasicular Module in a Pharm.D. Curriculum. Amer. J. Pharm. Edu. 64(1): 20-
26, 2000.
Allison, J.C.; Parteleno, P.A.; Streetman, D.S. Hypertension. In: Cardiology for the Non-Traditional Pharm. D. Editor: J.E. Sprague. Council of Ohio Colleges of Pharmacy. Columbus, OH. 1998.
Sprague, J.E.; Harrod, A.D.; Teconchuk, A.L. The pharmacology and abuse potential of ephedrine. Pharmacy Times. 64(5):72-80, 1998.
Sprague, J.E.; Everman, S.L.; Nichols, D.E. An Intregrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicol. 19(3):427-442, 1998.
Sprague, J.E. Teaching the pharmacology of angiotensin converting enzyme inhibitors for the treatment of hypertension. Amer. J. Pharm. Edu. 61:173-178, 1997.
Culbertson, J.L.; Sprague, J.E. Obsession with weight loss: an overview of anorexic agents through the years and into the future. Pharmacy Times. 63(6):65-77, 1997.
Faulkner, T.P.; Sprague, J.E. Application of several multimedia approaches to the teaching of CNS pharmacology: Parkinson’s disease and antiParkinson’s drugs. Amer. J. Pharm. Edu. 60(4):417-421, 1996.
Sprague, J.E.; Johnson, M.P.; Schmidt, C.J.; Nichols, D.E. Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochem. Pharmacol. 52(8):1271-1277; 1996.
Maickel, R.P.; Sprague, J.E. Role of ACTH fragments in alcohol consumption. In: Stress, Gender, and alcohol-seeking Behavior. Editors: W.A. Hunt & S. Zakhari. NIH Publications, 1995.
Marona-Lewicka, D.; Rhee, G.S.; Sprague, J.E.; Nichols, D.E. Psychostimulant-like effects of para-fluoroamphetamine. Eur. J. Pharmacol. 287:105-113; 1995.
Marona-Lewicka, D.; Rhee, G.S.; Sprague, J.E.; Nichols, D.E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav. 53(1):99-105; 1996.
Sprague, J.E.; Nichols, D.E. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long term serotonergic deficits. J. Pharmacol. Exp. Ther. 273(3):667-673;1995.
Sprague, J.E.; Nichols, D.E. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacol. 118:357-359;1995.
Sprague, J.E.; Huang, X.; Kanthasamy, A.; Nichols, D.E. Attenuation of 3,4-methylenedioxy-
methamphetamine (MDMA)-induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci. 55(15):1193-1198;1994.
Sprague, J.E.; Sharp, D.; Maickel, R.P. Cholinergic regulation of ethanol consumption in rats. Res. Commun. Chem. Pathol. Pharmacol. 15(1&2):1-8;1994.
PEER REVIEWED PUBLICATIONS CONTINUED:
Sprague, J.E.; Maickel, R.P. Effects of stress and Ebratide (Hoe-427) on free-choice ethanol consumption: comparison of Lewis and Sprague-Dawley rats. Life Sci. 55(11):873-878;1994.
Zabik, J.E.; Sprague, J.E.; Binkerd, K. Central and peripheral components of the inhibitory actions of 5HTP on ethanol consumption in the rat. Pharmacol. Biochem. Behav. 47(3):547-551;1994.
Sprague, J.E.; Fitzgerald, A.L.; Suckow, M.A.; Grigdesby, C.F.; Uetrecht, R.L.; Maickel, R.P. Pharmacological studies of centrifugation-induced analgesia. Pharmacol. Biochem. Behav. 46:911-915;1993.
Zabik, J. E.; Sprague, J.E.; Odio, M. Interactive dopaminergic and noradrenergic systems in the regulation of thirst in the rat. Physiol. Behav. 54(1):29-33;1993.
ABSTRACTS (Discontinued adding in 2004):
Rusyniak, D.E., Scrugg, S.L., and Sprague, J.E. Ecstasy’s effects on in-vitro and ex-vivo oxidative phophorylation in rodent skeletal muscle. SAEM abstract 99; 2004.
Woodside, B.L., Preston, A.S., Leifheit, M.C., and Sprague, J.E. Hippocampal serotonergic damage induced by ecstasy (MDMA): effects on spatial learning. Soc. Neurosci. Abstracts. 2003.
Sprague, J.E., Banks, M.L., Mills, E.M., and Rusyniak, D.E. 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) induced changes in striatal temperature and uncoupling protein (UCP) expression. Soc. Neurosci. Abstracts. 638.3, 2003.
Brown, A.W., Hrometz, S.L., and Sprague, J.E. The Role of Dopamine Deamination as the Source of Free-Radicals Responsible for MDMA-Mediated Serotonergic Neurotoxicity using an